Table 5.
Crude and adjusted ORs of severe COPD exacerbations associated with the current receipt with each type of oral hypoglycemic agent in monotherapy
| Cases (n = 2700) | Controls (n = 9272) | Crude OR (95% CI) |
Adjusted ORa (95% CI) |
|
|---|---|---|---|---|
| Current use of monotherapy, no (%)b | ||||
| Metformin | 346 (12.8) | 1242 (13.4) | 0.85 (0.73–0.99)d | 0.87 (0.74–1.02) |
| Sulfonylureas | 423 (15.7) | 1344 (14.5) | 1.08 (0.93–1.25) | 1.14 (0.97–1.34) |
| α-Glucosidase inhibitors | 34 (1.3) | 139 (1.5) | 0.77 (0.53–1.14) | 0.74 (0.50–1.12) |
| TZDs | 8 (0.3) | 33 (0.4) | 0.82 (0.38–1.79) | 0.84 (0.37–1.89) |
| DPP-4 inhibitors | 36 (1.3) | 74 (0.8) | 1.59 (1.04–2.41)d | 1.46 (0.94–2.27) |
| Meglitinides | 96 (3.6) | 252 (2.7) | 1.26 (0.98–1.62) | 1.05 (0.80–1.36) |
| Other classes of monotherapyc | Reference | Reference | ||
Abbreviations: OR, odds ratio; COPD, chronic obstructive pulmonary disease; CI confidence interval; No., Number; TZD, thiazolidinedione; DPP-4, dipeptidyl peptidase-4
a Adjusted for all covariates with standardized difference > 0.1 in Table 1
b Current use was defined as the end date of the most recent prescription within the 30 days prior to the index date
c Each antidiabetic agent monotherapy was separately compared with all of the other types of antidiabetic agents monotherapy combined
d p < 0.05